Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$2.17 USD
+0.05 (2.36%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $2.16 -0.01 (-0.46%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Cyclacel Pharmaceuticals, Inc. [CYCC]
Reports for Purchase
Showing records 1 - 20 ( 75 total )
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Specifies Fadraciclib Patient Targeting, Reformulating Plogosertib
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Fadraciclib Shows Efficacy Against CDKN2A, CDKN2B, MTAP Deletion Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Progress and Positive Clinical Results Defy Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress and Positive Clinical Results Defy Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Delivery of Encouraging Clinical Results Defies Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Positive Phase 1 Solid Tumor/Lymphoma Data with Fadraciclib & CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Takeaways Regarding Fadraciclib And CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 1 Oral Fadraciclib Data Shows Favorable Safety And Efficacy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Positive Early Solid Tumor/ Lymphoma Data with Fadraciclib & CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J